{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:04:06Z","timestamp":1790521446768,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.toxlet.2018.06.1069","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:42:01Z","timestamp":1529368921000},"page":"187-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Inter-individual differences in the susceptibility of primary human hepatocytes towards drug-induced cholestasis are compound and time dependent"],"prefix":"10.1016","volume":"295","author":[{"given":"C\u00e9line","family":"Parmentier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1159-5946","authenticated-orcid":false,"given":"Delilah F.G.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Heyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bachellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ingelman-Sundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysiane","family":"Richert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2018.06.1069_bib0005","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/hep.26160","article-title":"Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human heparg cells","volume":"57","author":"Anth\u00e9rieu","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0010","doi-asserted-by":"crossref","first-page":"25187","DOI":"10.1038\/srep25187","article-title":"Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease","volume":"6","author":"Bell","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0015","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/toxsci\/kfx289","article-title":"Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study","volume":"162","author":"Bell","year":"2018","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tiv.2015.07.016","article-title":"Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems","volume":"30","author":"Bellwon","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-2002-30099","article-title":"Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions","volume":"22","author":"Bohan","year":"2002","journal-title":"Semin Liver Dis."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejmech.2014.06.015","article-title":"Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds","volume":"83","author":"Bordessa","year":"2014","journal-title":"Eur J. Med. Chem."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.mpmed.2006.10.005","article-title":"Drugs that damage the liver","volume":"35","author":"Brind","year":"2007","journal-title":"Medicine"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tiv.2014.08.012","article-title":"Biokinetics of chlorpromazine in primary rat and human hepatocytes and human HepaRG cells after repeated exposure","volume":"30","author":"Broeders","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0045","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.tiv.2013.10.020","article-title":"Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: role of glycine conjugates","volume":"28","author":"Chatterjee","year":"2014","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0050","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.taap.2013.10.032","article-title":"Hepatocyte-based in vitro model for assessment of drug-induced cholestasis","volume":"274","author":"Chatterjee","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0055","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bbadis.2010.12.021","article-title":"Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease","volume":"1812","author":"Claudel","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0065","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1124\/dmd.111.040758","article-title":"In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans","volume":"40","author":"Dawson","year":"2012","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0075","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.1840080513","article-title":"Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic","volume":"8","author":"Freneaux","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0080","first-page":"379","article-title":"Mechanisms of hepatic transport of cyclosporin A: an explanation for its cholestatic action?","volume":"70","author":"Fricker","year":"1997","journal-title":"Yale J. Biol Med."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0085","first-page":"860","article-title":"Pharmacokinetics of cyclosporine from conventional and new microemulsion formulations in healthy volunteers","volume":"46","author":"Gulati","year":"1998","journal-title":"J. Assoc. Phys. India"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0090","doi-asserted-by":"crossref","first-page":"35434","DOI":"10.1038\/srep35434","article-title":"Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability","volume":"6","author":"Hendriks","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-3-642-00663-0_12","article-title":"Mechanisms of acetaminophen-induced liver necrosis","author":"Hinson","year":"2010","journal-title":"Handbook. Exp. Pharmacol."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051018","article-title":"Drug-induced liver injury: Cascade of events leading to cell death, Apoptosis or Necrosis","volume":"18","author":"Iorga","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12989-014-0056-2","article-title":"Hepatic toxicology following single and multiple exposure of engineered nanomaterials utilising a novel primary human 3D liver microtissue model","volume":"11","author":"Kermanizadeh","year":"2014","journal-title":"Part. Fibre Toxicol."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0110","first-page":"1561","article-title":"The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats","volume":"29","author":"Kostrubsky","year":"2001","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tiv.2015.09.005","article-title":"Biokinetics in repeated-dosing in vitro drug toxicity studies","volume":"30","author":"Kramer","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0120","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.2009.03381.x","article-title":"Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity","volume":"67","author":"Lafuente-Lafuente","year":"2009","journal-title":"Br J. Clin. Pharmacol."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0125","doi-asserted-by":"crossref","first-page":"C1764","DOI":"10.1152\/ajpcell.1994.266.6.C1764","article-title":"Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration","volume":"266","author":"LeCluyse","year":"1994","journal-title":"Am J. Physiol"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0130","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1345\/aph.1E072","article-title":"Second-generation thiazolidinediones and hepatotoxicity","volume":"38","author":"Marcy","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0135","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/clpt.2013.143","article-title":"Association of CYP2C9*2 with bosentan-induced liver injury","volume":"94","author":"Markova","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00204-012-0968-2","article-title":"Multi-cell type human liver microtissues for hepatotoxicity testing","volume":"87","author":"Messner","year":"2013","journal-title":"Arch Toxicol."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0145","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.vascn.2015.03.002","article-title":"Drug-induced cholestasis detection in cryopreserved rat hepatocytes in sandwich culture","volume":"73","author":"Oorts","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tiv.2016.03.008","article-title":"Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes","volume":"34","author":"Oorts","year":"2016","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0155","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/hep.24229","article-title":"Drug-induced cholestasis","volume":"53","author":"Padda","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0160","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1124\/dmd.113.052415","article-title":"Transcriptomic hepatotoxicity signature of chlorpromazine after short- and long-term exposure in primary human sandwich cultures","volume":"41","author":"Parmentier","year":"2013","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0165","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1007\/s00204-017-1930-0","article-title":"Evaluation of transcriptomic signature as a valuable tool to study drug-induced cholestasis in primary human hepatocytes","volume":"91","author":"Parmentier","year":"2017","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0170","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/toxsci\/kft197","article-title":"Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP\/ABCB11)","volume":"136","author":"Pedersen","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0175","article-title":"In vitro kinetics of amiodarone and its major metabolite in two human liver cell models after acute and repeated treatments","author":"Pomponio","year":"2014","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00004836-199403000-00029","article-title":"Does ursodeoxycholic acid have a place in the treatment of amiodarone-induced cholestasis?","volume":"18","author":"Reshef","year":"1994","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.toxlet.2016.06.1127","article-title":"Cytotoxicity evaluation using cryopreserved primary human hepatocytes in various culture formats","volume":"258","author":"Richert","year":"2016","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0190","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00002018-200124120-00002","article-title":"Hepatotoxicity with thiazolidinediones: is it a class effect?","volume":"24","author":"Scheen","year":"2001","journal-title":"Drug. Saf."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0195","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.stemcr.2015.04.001","article-title":"Small-molecule-driven hepatocyte differentiation of human pluripotent stem cells","volume":"4","author":"Siller","year":"2015","journal-title":"Stem Cell. Reports"},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0200","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3109\/03602530903491881","article-title":"Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity","volume":"42","author":"Swift","year":"2010","journal-title":"Drug. Metab. Rev."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0205","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.toxlet.2015.01.006","article-title":"Understanding the biokinetics of ibuprofen after single and repeated treatments in rat and human in vitro liver cell systems","volume":"233","author":"Truisi","year":"2015","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0210","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00204-018-2201-4","article-title":"In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist","volume":"92","author":"Vinken","year":"2018","journal-title":"Arch Toxicol."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0215","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1096\/fj.201601375R","article-title":"Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics","volume":"31","author":"Vorrink","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0220","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/clpt.2011.63","article-title":"Drug safety sciences and the bottleneck in drug development","volume":"89","author":"Watkins","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0225","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/toxsci\/kfn109","article-title":"Cellular imaging predictions of clinical drug-induced liver injury","volume":"105","author":"Xu","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.taap.2013.01.018","article-title":"Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats","volume":"268","author":"Yamazaki","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0235","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/jps.23584","article-title":"An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters","volume":"102","author":"Yang","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.toxlet.2018.06.1069_bib0240","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/bdd.701","article-title":"Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes","volume":"31","author":"Ye","year":"2010","journal-title":"Biopharm. Drug. Dispos."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427418313080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427418313080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T07:09:44Z","timestamp":1693724984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427418313080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":48,"alternative-id":["S0378427418313080"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2018.06.1069","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inter-individual differences in the susceptibility of primary human hepatocytes towards drug-induced cholestasis are compound and time dependent","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2018.06.1069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}